HTX-034 (bupivacaine/meloxicam/adrenaline)

About Heron Therapeutics

Heron Therapeutics is a publicly traded biopharmaceutical company dedicated to developing non-opioid, long-acting therapeutics for acute care and oncology supportive care. The company has successfully transitioned to a commercial entity with two marketed products and a pipeline leveraging its proprietary Biochronomer® sustained-release delivery technology. Heron's strategic focus is on expanding the commercial footprint of its approved products while advancing its pipeline candidates to address complex pain and nausea/vomiting challenges, aiming to reduce reliance on systemic opioids and improve patient outcomes.

Therapeutic Areas